Iterum Therapeutics (ITRM) Given Media Impact Rating of -0.05
Headlines about Iterum Therapeutics (NASDAQ:ITRM) have been trending somewhat negative on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iterum Therapeutics earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5029240798112 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Iterum Therapeutics traded down $0.10, hitting $12.10, during midday trading on Thursday, Marketbeat.com reports. The stock had a trading volume of 1,713 shares, compared to its average volume of 67,317. Iterum Therapeutics has a 52 week low of $11.23 and a 52 week high of $13.00.
In other news, Director Patrick J. Heron bought 456,099 shares of Iterum Therapeutics stock in a transaction that occurred on Wednesday, May 30th. The stock was purchased at an average cost of $13.00 per share, with a total value of $5,929,287.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Corey N. Fishman bought 3,000 shares of Iterum Therapeutics stock in a transaction that occurred on Wednesday, May 30th. The stock was purchased at an average cost of $13.00 per share, with a total value of $39,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 965,099 shares of company stock valued at $12,546,287.
There is no company description available for Iterum Therapeutics PLC.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.